Medical Treatment ~ Breast Cancer
~ Genetics of Breast & Ovarian Cancer

Return to More Current References

Older References


    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Molecular pathways: understanding the role of rad52 in homologous recombination for therapeutic advancement.
    • Lok BH, Powell SN.
    • Clin Cancer Res. 2012 Dec 1;18(23):6400-6. doi: 10.1158/1078-0432.CCR-11-3150. Epub 2012 Oct 15.
    • PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    • Węsierska-Gądek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M.
    • Biochem Pharmacol. 2012 Nov 15;84(10):1318-31. doi: 10.1016/j.bcp.2012.07.024. Epub 2012 Aug 14.
    • A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.
    • Ratanaphan A.
    • Int J Mol Sci. 2012 Nov 14;13(11):14898-916. doi: 10.3390/ijms131114898.
    • Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
    • Turner NC, Tutt AN.
    • Breast Cancer Res. 2012 Nov 13;14(6):115. doi: 10.1186/bcr3332.

    Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

    • Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.
    • Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F.
    • Cancer Res. 2012 Nov 1;72(21):5547-55. doi: 10.1158/0008-5472.CAN-12-0934. Epub 2012 Sep 7.
    • PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition.
    • Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.
    • Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

    Comment:

    The promise of combining inhibition of PI3K and PARP as cancer therapy.

    Comment:

    Therapeutics: PI3K-PARP combination.

    • Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer.
    • Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.
    • Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.

    Comment:

    The promise of combining inhibition of PI3K and PARP as cancer therapy.

    Comment:

    Therapeutics: PI3K-PARP combination.

    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • The management of menopausal symptoms in breast cancer survivors: case-based approach.
    • Lammerink EA, de Bock GH, Schröder CP, Mourits MJ.
    • Maturitas. 2012 Nov;73(3):265-8. doi: 10.1016/j.maturitas.2012.07.010. Epub 2012 Aug 9.
    • Review
    • BRCA1 and microRNAs: emerging networks and potential therapeutic targets.
    • Chang S, Sharan SK.
    • Mol Cells. 2012 Nov;34(5):425-32. doi: 10.1007/s10059-012-0118-y. Epub 2012 Jul 24.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
    • Nowsheen S, Cooper T, Stanley JA, Yang ES.
    • PLoS One. 2012;7(10):e46614. doi: 10.1371/journal.pone.0046614. Epub 2012 Oct 11.
    • PPARγ agonists target aromatase via both PGE2 and BRCA1.
    • Margalit O, Wang D, Dubois RN.
    • Cancer Prev Res (Phila). 2012 Oct;5(10):1169-72. doi: 10.1158/1940-6207.CAPR-12-0365.
    • Therapeutics: PI3K-PARP combination.
    • Alderton GK.
    • Nat Rev Cancer. 2012 Oct;12(10):658. doi: 10.1038/nrc3372.
    • Comment

    • Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.
    • Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM.
    • Virchows Arch. 2012 Oct;461(4):425-31. doi: 10.1007/s00428-012-1311-2. Epub 2012 Sep 12.
    • EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
    • Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S.
    • PLoS One. 2012;7(9):e45248. doi: 10.1371/journal.pone.0045248. Epub 2012 Sep 17.
    • HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.
    • Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES.
    • Cancer Res. 2012 Sep 15;72(18):4796-806. doi: 10.1158/0008-5472.CAN-12-1287.
    • Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
    • Sousa B, Cardoso F.
    • Ann Oncol. 2012 Sep;23 Suppl 10:x237-42.
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • Systemic therapy options in BRCA mutation-associated breast cancer.
    • Bayraktar S, Glück S.
    • Breast Cancer Res Treat. 2012 Sep;135(2):355-66. doi: 10.1007/s10549-012-2158-6. Epub 2012 Jul 12.
    • Review
    • Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
    • Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.
    • Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.
    • Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    • Clark CC, Weitzel JN, O'Connor TR.
    • Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.
    • Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    • Stecklein SR, Jensen RA.
    • Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9.
    • Review
    • BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    • Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.
    • Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.
    • BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
    • Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.
    • Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.
    • Cancer treatment according to BRCA1 and BRCA2 mutations.
    • Maxwell KN, Domchek SM.
    • Nat Rev Clin Oncol. 2012 Aug 14;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.
    • Review
    • Neoadjuvant treatments for triple-negative breast cancer (TNBC).
    • von Minckwitz G, Martin M.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi35-9.
    • Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
    • Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA.
    • Breast Cancer Res. 2012 Jul 20;14(4):R110. doi: 10.1186/bcr3231.

    Editorial:

    Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

    • Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    • Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R.
    • Anticancer Agents Med Chem. 2012 Jul 1;12(6):672-7.
    • Review
    • Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.
    • Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.
    • Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.
    • BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
    • Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, Daneshmand M, Hanson J, Nabavi M, Parolin D, Mallick R, Verma S.
    • Oncol Lett. 2012 Jul;4(1):141-145. Epub 2012 Apr 26.
    • Options in breast cancer local therapy: who gets what?
    • Jatoi I.
    • World J Surg. 2012 Jul;36(7):1498-502. doi: 10.1007/s00268-012-1530-3.
    • Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
    • Kimbung S, Biskup E, Johansson I, Aaltonen K, Ottosson-Wadlund A, Gruvberger-Saal S, Cunliffe H, Fadeel B, Loman N, Berglund P, Hedenfalk I.
    • Cancer Lett. 2012 Jun 28;319(2):232-41. doi: 10.1016/j.canlet.2012.01.015. Epub 2012 Jan 20.
    • [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    • Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.
    • Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84.
    • [PARP inhibitors--theoretical basis and clinical application].
    • Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.
    • Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21.
    • Dissecting the heterogeneity of triple-negative breast cancer.
    • Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M.
    • J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26.
    • Review
    • Pathological complete response in younger and older breast cancer patients.
    • Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z.
    • Arch Med Sci. 2012 May 9;8(2):310-5. doi: 10.5114/aoms.2012.28559.
    • Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
    • Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.
    • Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.
    • Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
    • Alli E, Ford JM.
    • DNA Repair (Amst). 2012 May 1;11(5):522-4. doi: 10.1016/j.dnarep.2012.02.003. Epub 2012 Mar 14.
    • [PARP inhibitors and breast cancer: update and perspectives].
    • Gonçalves A.
    • Bull Cancer. 2012 Apr 1;99(4):441-51. doi: 10.1684/bdc.2012.1553.
    • Review, [Article in French]
    • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    • Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.
    • Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.
    • Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
    • Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, D'Amico M, Mazzoni E, Marino A, Sponziello F, Morelli F, Lombardi L, Silvestris N, Cinieri S.
    • Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S83-9. doi: 10.1517/14728222.2011.648925. Epub 2012 Mar 23.
    • Review
    • CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    • Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    • Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
    • Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
    • Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.
    • A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
    • Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T.
    • Cancer Sci. 2012 Mar;103(3):504-9. doi: 10.1111/j.1349-7006.2011.02179.x. Epub 2012 Jan 30.
    • The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C.
    • Cancer. 2012 Feb 15;118(4):899-907. doi: 10.1002/cncr.26351. Epub 2011 Jul 14.

    Press: Some BRCA1 Carriers Less Sensitive to Taxane. (Medscape Reuters)

    • Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
    • Zhang M, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Breast Cancer Res Treat. 2012 Feb;132(1):335-40. doi: 10.1007/s10549-011-1887-2. Epub 2011 Nov 25.
    • Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    • Hall PS, McCabe C, Stein RC, Cameron D.
    • J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.
    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.
    • Hiller DJ, Chu QD.
    • Int J Breast Cancer. 2012;2012:829315. doi: 10.1155/2012/829315. Epub 2011 Oct 25.